15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.

      Oncology Reports
      Antineoplastic Agents, pharmacology, Blotting, Western, Carcinoma, Hepatocellular, metabolism, Cell Line, Tumor, Cell Proliferation, drug effects, Cell Separation, Electrophoretic Mobility Shift Assay, Enzyme Activation, Flow Cytometry, Fluorouracil, Humans, Liver Neoplasms, NF-kappa B, Reverse Transcriptase Polymerase Chain Reaction, Vitamin K 2, analogs & derivatives

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings. Since menatetrenone, an analogue of vitamin K2 (VK2), inhibits growth of cancer cells including HCC cells in vitro and in vivo, we examined VK2 modulation of HCC cell response to 5-FU. VK2 pretreatment dose-dependently enhanced growth-inhibition by 5-FU through a G1 cell cycle arrest. VK2 inhibited 5-FU-induced NF-κB activation and cyclin D1 expression. Therefore, combination of VK2 and 5-FU might represent a new therapeutic strategy for patients with HCC.

          Related collections

          Author and article information

          Comments

          Comment on this article